AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02057523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
Study NCT04342793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT04342793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-L1023 1,200mg
Description: ALS-L1023
Study NCT04342793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-L1023 1,800mg
Description: ALS-L1023
Study NCT02301260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training (SPT)
Study NCT02301260 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
Study NCT03487354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol
Study NCT02744378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 0.1%
Description: This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
Study NCT02744378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 0.05%
Description: This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
Study NCT02835833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib will be given twice daily at either 150 mg or 200 mg.
Study NCT02835833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given at 15 mg/kg
Study NCT03407664 — intervention group
Intervention type: OTHER
Intervention: this field is not applicable
Description: We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
Study NCT02313233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Umooze
Description: Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
Study NCT04345120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-008 matching placebo
Description: SY-008 matching placebo
Study NCT02313233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
Study NCT03392545 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined immune adjuvants and radiation
Description: 24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
Study NCT02292927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post-intervention arm = Prehabilitation
Description: Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
Study NCT00211185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
Study NCT00211185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Study NCT00211185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Study NCT00211185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered IV at a dosage of 1.4 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Study NCT00211185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
Study NCT00211185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm\^2) for 2 days post-nadir.
Study NCT01466933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive parenting
Description: On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
Study NCT01466933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Development
Description: On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
Study NCT02667197 — intervention group
Intervention type: OTHER
Intervention: Algorithm to determine overdose from opioid abuse
Study NCT02502123 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered in this study.
Study NCT03168607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
Study NCT04617561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid
Description: Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
Study NCT03852056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MFP Fluoride toothpaste
Description: Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
Study NCT03852056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
Study NCT04617561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
Description: Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
Study NCT02479321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDT based on noninvasive monitoring
Description: Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders.
Study NCT02596867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propanolol
Description: Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
Study NCT02479321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System ClearSight® and Platform EV Clinic 1000®
Description: Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.
Study NCT03390218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Assistance Online
Description: protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
Study NCT03390218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Individual and group therapy, generic in nature
Study NCT01927926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey-protein & polydextrose snack
Description: Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
Study NCT01927926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control snack
Description: Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
Study NCT02218294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161
Study NCT03775889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gardening
Description: Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
Study NCT04727892 — intervention group
Intervention type: PROCEDURE
Intervention: epilepsy surgery
Description: Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.
Study NCT02021097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
Description: Tablet, orally, opd
Study NCT02021097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg
Description: Tablet, orally, opd
Study NCT01681173 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: 200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
Study NCT01681173 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 200ml Placebo, BID, over 24 months
Study NCT04894487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY
Description: Using of baby mobile and listening Brahms Lullaby during sternum dressing process
Study NCT02244021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRENTUXIMAB VEDOTIN
Description: Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT.
Study NCT02796157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
Description: Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
Study NCT02796157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with Xience everolimus-eluting metallic stent
Description: Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
Study NCT03270397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic course The group- theory and practice
Description: Active participation in the course The group- theory and practice.
Study NCT01576250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unilateral lower limb suspension
Description: This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
Study NCT00122460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)
Description: Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
Study NCT00122460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum (Cisplatin or Carboplatin) + 5-FU
Description: All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
Study NCT01115751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2780301
Description: Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression.
Study NCT01947972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Tailored protein fortification
Description: 4-4.5g of protein/kg/d
Study NCT04822831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 45 Degree Semi-recumbent Position With Upper Limb Exercise Training
Description: The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
Study NCT04822831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training
Description: The control group was with usual treatment.
Study NCT04439682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
Study NCT04439682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
Study NCT00825916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100 Drug Product
Description: Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study NCT00825916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100 Drug Product
Description: Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study NCT00825916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study NCT01653067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Temsirolimus, DHAP, intravenous
Description: Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
Study NCT02013518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
Study NCT02013518 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioural Therapy
Description: 11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
Study NCT01742611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT01884467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Comparison of Gentamicin versus placebo
Study NCT01884467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01414140 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Women inserted Mirena for intrauterine contraception.
Study NCT04866498 — intervention group
Intervention type: DRUG
Intervention: Infusion Intravenous
Study NCT02212210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Study NCT02212210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01207297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration.
Study NCT01207297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
Study NCT03404141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent craft
Description: Midwife-guided classes for pregnant women about pregnancy and childbirth
Study NCT03404141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
Study NCT03418831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene Hydrochloride
Description: 60 mg per capsule (1 tablet daily) for 12 weeks
Study NCT03418831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 12 weeks
Study NCT04141969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RLP
Description: RLP nutraceutical
Study NCT04141969 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert brown powder
Study NCT01657513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subjects will receive either infliximab, adalimumab or etanercept
Description: The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines